The medical chiefs and managers of a number of German heart treatment centers have been accused of defrauding the public-sector health funds out of millions of Deutschemarks and of having accepted bribes from manufacturers of pacemakers. They are to be investigated by the federal parliament's health committee, at a special hearing.
The federation of local health insurance funds claims it has long suspected that the price of pacemakers was being set too high, and was seeking to have the prices reduced. Pacemaker products sold in Germany are produced almost exclusively by US manufacturers.
The announcement of the inquiry into the pacemaker bribe claims was followed almost immediately by statements from health funds indicating that other forms of health service fraud involving other types of medical products "could be practised." However, karsten Vilmar, president of the federal chamber of doctors, said legal action would be taken against the health funds unless they backed up their general claims with concrete evidence.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze